Current Neuro-Oncology

Volume 25 Number 3
15 February 2023

Home > Publications > Current Neuro-Oncology > Volume 25, Year 2023 > Number 3, 15 February

Alanen E, Heikkinen S, Nurminen R, Nykter M, Haapasalo H, Hirvonen E, Pitkäniemi J, Rautajoki KJ.
Early-onset grade 2-3 diffuse gliomas and schwannomas increase the risk of central nervous system tumors among the patients' relatives.
Neurooncol Adv. 2023 Feb 1;5(1):vdad008. doi: 10.1093/noajnl/vdad008. PMID: 36950216. Observational study. ˍ

Perwein T, Giese B, Nussbaumer G, von Bueren AO, van Buiren M, Benesch M, Kramm CM.
How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
J Neurooncol. 2023 Feb 1
. doi: 10.1007/s11060-023-04241-6. PMID: 36720762. Observational study. ˍ

Santiago RACB, Ali A, Ibrahim B, Mandel M, Muhsen B, Obrzut M, Ranjan S, Borghei-Razavi H, Adada B.
Safety of craniotomy for brain tumor resection in octogenarians and older patients - a matched - cohort analysis.
Int J Neurosci. 2023 Feb 1:1-7
. doi: 10.1080/00207454.2023.2174866. PMID: 36724879. Observational study˰ ˍ

Blakstad H, Brekke J, Rahman MA, Arnesen VS, Miletic H, Brandal P, Lie SA, Chekenya M, Goplen D.
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions.
PLoS One. 2023 Feb 2;18(2):e0281166∟. doi: 10.1371/journal.pone.0281166
. PMID: 36730349. Observational study. ˍ

Bosio A, Cerretti G, Padovan M, Caccese M, Denaro L, Chioffi F, Della Puppa A, Aldegheri V, Guarneri V, Zagonel V, Lombardi G.
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study.
Clin Oncol (R Coll Radiol). 2023 Feb 2:S0936-6555(23)00017-1
. doi: 10.1016/j.clon.2023.01.012. PMID: 36858930. Observational study. ˍ

Fanucci K, Pilat MJ, Shyr D, Shyr Y, Boerner S, Li J, Durecki D, Drappatz J, Puduvalli V, Lieberman FS, Gonzalez J, Giglio P, Ivy SP, Bindra RS, Omuro A, LoRusso P.
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and DH2-mutant Glioma.
Cancer Res Commun. 2023 Feb 2;3(2):192-201. doi: 10.1158/2767-9764.CRC-22-0436. PMID: 36968138. Interventional study. ˍ

Giambra M, Di Cristofori A, Conconi D, Marzorati M, Redaelli S, Zambuto M, Rocca A, Roumy L, Carrabba G, Lavitrano M, Roversi G, Giussani C, Bentivegna A.
Insights into the Peritumoural Brain Zone of Glioblastoma: CDK4 and EXT2 May Be Potential Drivers of Malignancy.
Int J Mol Sci. 2023 Feb 2;24(3):2835
. doi: 10.3390/ijms24032835. PMID: 36769158. Laboratory investigation. ˍ

Douw L, Breedt LC, Zimmermann MLM.
Cancer meets neuroscience: the association between glioma occurrence and intrinsic brain features.
Brain. 2023 Feb 3:awad034
. doi: 10.1093/brain/awad034. PMID: 36732287. Comment. ˍ
Refers to:
Romero-Garcia R, et al Transcriptomic and connectomic correlates of differential spatial patterning among gliomas. Brain. 2022 Oct 18:awac378. doi: 10.1093/brain/awac378. PMID: 36256589. Laboratory investigation. ˍ

Elsaka R, Kitagwa JM, Refaat T, Mahmoud AA, Shaikh H, Meheissen MAM, Elsaid AA.
Impact of Extended Adjuvant Temozolamide Beyond 6 Months in the Management of Glioblastoma Patients.
Am J Clin Oncol. 2023 Feb 3
. doi: 10.1097/COC.0000000000000983. PMID: 36735492. Observational study. ˍ

Ma S, Patell R, Miller E, Ren S, Marquez-Garcia J, Panoff S, Sharma R, Pinson A, Elavalakanar P, Weber G, Uhlmann E, Neuberg D, Soman S, Zwicker JI.
Antiplatelet medications and intracranial hemorrhage in patients with primary brain tumors.
J Thromb Haemost. 2023 Feb 3:S1538-7836(23)00085-5
. doi: 10.1016/j.jtha.2023.01.031. PMID: 36740041. Observational study. ˍ


Ramesh KK, Huang V, Rosenthal J, Mellon EA, Goryawala M, Barker PB, Gurbani SS, Trivedi AG, Giuffrida AS, Schreibmann E, Han H, de le Fuente M, Dunbar EM, Holdhoff M, Kleinberg LR, Shu HG, Shim H, Weinberg BD.
A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma.
Tomography. 2023 Feb 6;9(1):362-374
. doi: 10.3390/tomography9010029. PMID: 36828381. Interventional study. ˍ

Tonning Olsson I, Lundgren J, Hjorth L, Munck Af Rosenschöld P, Hammar Å, Perrin S.
Neurocognitive development after pediatric brain tumor – a longitudinal, retrospective cohort study.
Child Neuropsychol. 2023 Feb 6:1-23
. doi: 10.1080/09297049.2023.2172149. PMID: 36744788. Observational study. ˍ

Calò P, Pianton N, Basle A, Vasiljevic A, Barritault M, Beuriat PA, Faure-Conter C, Leblond P.
Bevacizumab as Single Agent in Children and Teenagers with Optic Pathway Glioma.
Cancers (Basel). 2023 Feb 7;15(4):1036
. doi: 10.3390/cancers15041036. PMID: 36831379. Observational study. ˍ

Mahase SS, Roytman M, Roth O'Brien D, Ivanidze J, Schwartz TH, Pannullo SC, Ramakrishna R, Magge RS, Williams N, Fine HA, Chiang GC, Knisely JPS.
Concurrent immunotherapy and re-irradiation utilizing stereotactic body radiotherapy for recurrent high-grade gliomas.
Cancer Rep (Hoboken). 2023 Feb 7:e1788
. doi: 10.1002/cnr2.1788. PMID: 36750401. Observational study. ˍ

Mani S, Chatterjee A, Dasgupta A, Shirsat N, Epari S, Chinnaswamy G, Gupta T.
WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?
Oncotarget. 2023 Feb 7;14:105-110
. doi: 10.18632/oncotarget.28360. PMID: 36749287. Laboratory investigation. ˍ


Melhem JM, Tahir A, Calabrese E, Granovskaya I, Atenafu EG, Sahgal A, Lim-Fat MJ, Perry JR.
Dose-dependent efficacy of bevacizumab in recurrent glioblastoma.
J Neurooncol. 2023 Feb 7
. doi: 10.1007/s11060-023-04248-z. PMID: 36749445. Observational study˰ ˍ

Mou B, Cruz-Lim EM.
Recurrent Extraneural Metastatic Medulloblastoma in an Adult Presenting With a Superscan and Treated With Radium-223.
Cureus. 2023 Feb 7;15(2):e34732. doi: 10.7759/cureus.34732. PMID: 36909024. Case report. ˍ


Park J, Lee D, Shim JK, Yoon SJ, Moon JH, Kim EH, Chang JH, Lee SJ, Kang SG.
Mesenchymal Stem-Like Cells Derived from the Ventricle More Effectively Enhance Invasiveness of Glioblastoma Than Those Derived from the Tumor.
Yonsei Med J. 2023 Feb 7;64(3):157-166
. doi: 10.3349/ymj.2022.0430. PMID: 36825341. Laboratory investigation. ˍ

Zhang P, Duan Y, Gu G, Qu L, Xiao D, Xi T, Pan C, Liu Y, Zhang L.
Clinical, pathological, and radiological features of 80 pediatric diffuse intrinsic pontine gliomas: A single-institute study.
Front Oncol. 2023 Feb 7;13:1007393
. doi: 10.3389/fonc.2023.1007393. PMID: 36824137. Observational study. ˍ


Fisher PG.
When Can We Retire 3,600 cGy Craniospinal Irradiation in Medulloblastoma?
J Clin Oncol. 2023 Feb 8:JCO2300008
. doi: 10.1200/JCO.23.00008. PMID: 36753694. Editorial. ˍ
Refers to:
Coltin H, et al., The Burden of Surviving Childhood Medulloblastoma: A Population-Based, Matched Cohort Study in Ontario, Canada. J Clin Oncol. 2023 Jan 25:JCO2202466. doi: 10.1200/JCO.22.02466. PMID: 36696605. Observational study˰ ˍ

van der Meer P, Dirven L, Fiocco M, Vos MJ, Kouwenhoven MCM, van den Bent MJ, Taphoorn MJB, Koekkoek JAF.
Effectiveness of Antiseizure Medication Triple Therapy in Glioma Patients With Refractory Epilepsy: An Observational Cohort Study.
Neurology. 2023 Feb 8:10.1212/WNL.0000000000206852
. doi: 10.1212/WNL.0000000000206852. PMID: 36754633. Observational study. ˍ

Zhang C, Deng Z, Yang Z, Xie J, Hou Z.
A nomogram model to predict the acute venous thromboembolism risk after surgery in patients with glioma.
Thromb Res. 2023 Feb 9;224:21-31
. doi: 10.1016/j.thromres.2023.02.002. PMID: 36805800. Observational study˰ ˍ

Liu Y, Sun P, Zhou M, Du J, Zeng G.
Pediatric spinal cord diffuse midline glioma with H3 K27M-alteration with leptomeningeal dissemination: a rare case with intracranial hypertension onset and no spinal cord-related symptom.
Childs Nerv Syst. 2023 Feb 10
. doi: 10.1007/s00381-023-05851-1. PMID: 36759369. Case report˰ ˍ

Uetani H, Azuma M, Khant ZA, Watanabe Y, Kudo K, Kadota Y, Yokogami K, Takeshima H, Kuroda JI, Shinojima N, Hamasaki T, Mukasa A, Hirai T.
Importance of Age and Noncontrast-Enhancing Tumor as Biomarkers for Isocitrate Dehydrogenase-Mutant Glioblastoma: A Multicenter Study.
J Comput Assist Tomogr. 2023 Feb 10. doi: 10.1097/RCT.0000000000001456. PMID: 36877775. Observational study. ˍ

Winnicki C, Leblond P, Bourdeaut F, Pagnier A, Paluenzela G, Chastagner P, Duhil-De Benaze G, Min V, Sudour-Bonnange H, Piette C, Entz-Werle N, Chabaud S, André N.
Retrospective National "Real Life" Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol.
J Clin Med. 2023 Feb 10;12(4):1415
. doi: 10.3390/jcm12041415. PMID: 36835950. Observational study. ˍ

Van Gool SW, Makalowski J, Van de Vliet P, Van Gool S, Sprenger T, Schirrmacher V, Stuecker W.
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience.
Cancers (Basel). 2023 Feb 13;15(4):1194
. doi: 10.3390/cancers15041194. PMID: 36831536. Observational study. ˍ

Yahia-Cherif M, Luce S, De Witte O, Sadeghi-Meibodi N, Leurquin-Sterk G, Lefranc F.
Late-line treatment with bevacizumab alone or in combination with chemotherapy in recurrent high-grade gliomas.
Acta Neurochir (Wien). 2023 Feb 13
. doi: 10.1007/s00701-023-05524-7. PMID: 36781461. Observational study˰ ˍ

Faghihjouibari M, Khadivi M, Rouhani R, Pazoki Toroudi H, Nazari M, Sadeghian M, Abolfazli M.
Comparison of Efficacy and Safety of Levetiracetam Versus Phenytoin for Post-craniotomy Seizure Prophylaxis.
Med J Islam Repub Iran. 2023 Feb 14;37:7
. doi: 10.47176/mjiri.37.7. PMID: 37123333. Observational study. ˍ

Renovanz M, Kurz SC, Rieger J, Walter B, Becker H, Hille H, Bombach P, Rieger D, Grosse L, Häusser L, Skardelly M, Merk DJ, Paulsen F, Hoffmann E, Gani C, Neumann M, Beschorner R, Rieß O, Roggia C, Schroeder C, Ossowski S, Armeanu-Ebinger S, Gschwind A, Biskup S, Schulze M, Fend F, Singer S, Zender L, Lengerke C, Brucker SY, Engler T, Forschner A, Stenzl A, Kohlbacher O, Nahnsen S, Gabernet G, Fillinger S, Bender B, Ernemann U, Öner Ö, Beha J, Malek HS, Möller Y, Ruhm K, Tatagiba M, Schittenhelm J, Bitzer M, Malek N, Zips D, Tabatabai G.
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system.
Neurooncol Adv. 2023 Feb 14;5(1):vdad012. doi: 10.1093/noajnl/vdad012. PMID: 36915613. Interventional study. ˍ


Ubaldi L, Saponaro S, Giuliano A, Talamonti C, Retico A.
Deriving quantitative information from multiparametric MRI via Radiomics: Evaluation of the robustness and predictive value of radiomic features in the discrimination of low-grade versus high-grade gliomas with machine learning.
Phys Med. 2023 Feb 14;107:102538
. doi: 10.1016/j.ejmp.2023.102538. PMID: 36796177. Observational study˰ ˍ

Bagley SJ.
Phase 2 trials in the era of glioblastoma immunotherapy: New mechanisms of action, familiar challenges in trial design and tumor response assessment.
Neuro Oncol. 2023 Feb 15:noad043. doi: 10.1093/neuonc/noad043. PMID: 36789741. Editorial˰ ˍ
°Sampson JH, et al.,
Targeting the IL4 Receptor with MDNA55 in Patients with Recurrent Glioblastoma: Results of a Phase 2b Trial. Neuro Oncol. 2023 Jan 14:noac285. doi: 10.1093/neuonc/noac285. PMID: 36640127. Interventional study. ˍ

Bărăian AI, Iacob BC, Sorițău O, Tomuță I, Tefas LR, Barbu-Tudoran L, Șușman S, Bodoki E.
Ruxolitinib-Loaded Imprinted Polymeric Drug Reservoir for the Local Management of Post-Surgical Residual Glioblastoma Cells.
Polymers (Basel). 2023 Feb 15;15(4):965
. doi: 10.3390/polym15040965. PMID: 36850247. Laboratory investigation. ˍ

Haskell-Mendoza AP, Srinivasan ES, Lerner EC, Edwards RM, Schwalb AM, Jackson JD, Hardigan AA, Vaios EJ, Fecci PE.
Risk of Tract Seeding Following Laser Interstitial Thermal Therapy for Brain Tumors.
Neurosurgery. 2023 Feb 15
. doi: 10.1227/neu.0000000000002403. PMID: 36790207. Observational study˰ ˍ


Lepski G, Bergami-Santos PC, Pinho MP, Chauca-Torres NE, Evangelista GCM, Teixeira SF, Flatow E, de Oliveira JV, Fogolin C, Peres N, Arévalo A, Alves VAF, Barbuto JAM.
Adjuvant Vaccination with Allogenic Dendritic Cells Significantly Prolongs Overall Survival in High-Grade Gliomas: Results of a Phase II Trial.
Cancers (Basel). 2023 Feb 15;15(4):1239
. doi: 10.3390/cancers15041239. PMID: 36831580. Interventional study. ˍ

Pasqualetti F, Zanotti S.
Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination.
Br J Cancer. 2023 Feb 15. doi: 10.1038/s41416-023-02194-1. PMID: 36792723. Comment. ˍ
Refers to:
Liau LM, et al., Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5370. PMID: 36394838. Interventional study. ˍ